Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-8

Of particular interest is the fact that the quarterly makes no mention of partnership/ investor talks which were, up to now, always part of the presentation, see below from end of August.

Engagement with the world's leading business development partners and life science investors to establish the Company as a global leader in Ribonucleic Acid (RNA) therapeutics. The Company anticipates these engagements will create meaningful opportunities to more quickly progress and expand the Company's science and development programs.


Assumed that current talks would have failed, the natural progression of things would be to continue to pursue the engagement, hence keeing the lookout of engagement going.
To fall silent though on all partnering/ investor ongoings over the past 3 months inside the quarterly, with a supressed share price ever since resembling a TO in the making, one can only come to the conclusion that events are in motion and those anticipated opportunities now fall under the veil of confidentiality.

all IMO